Myeloma
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
Published in Blood Weekly, July 12th, 2007
Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, announced results demonstrating that ACE-011, a novel anabolic bone agent for the treatment of bone loss, preserved bone mass and architecture in a murine model of multiple myeloma. Multiple myeloma is a malignancy of plasma cells in the bone marrow that disrupts normal bone marrow function resulting in fractures, vertebral compressions and bone pain. The data were presented today at the 11th International Myeloma Workshop in Kos, Greece.
"The positive results from this study support the growing body of evidence that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-07-12)
More Articles from Blood Weekly
- Cord Blood
Cord blood may preserve insulin levels in children with type 1 diabetes - Acute Lymphoblastic Leukemia
CombiMatrix Molecular Diagnostics Launches HemeScan Ploidy Test for the Management of Acute Lymphoblastic Leukemia - Cancer
Kiadis Pharma Raises 15 million to Advance Oncology Pipeline - Cancer
Kiadis Pharma Raises euro 15 million to Advance Oncology Pipeline - Chronic Lymphocytic Leukemia
Cephalon Announces Plans for New NDA Filing for TREANDA - Chronic Lymphocytic Leukemia
The Leukemia & Lymphoma Society Offers Program on Chronic Lymphocytic Leukemia - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
